Are Galunisertib Worth The Money?

The study was conducted on 26 patients (age range 35�C58?years) whose ED was diagnosed on the basis of an international index of erectile function (IIEF-5) score http://www.selleckchem.com/products/z-vad-fmk.html group made up of 23 healthy subjects. In both groups, brachial artery flow-mediated dilatation (FMD) was evaluated, and a sample of peripheral blood was withdrawn for circulating EPC count. All patients with ED were then treated with tadalafil (20?mg three times a week for 3?months). The evaluation of brachial FMD and EPC counts were performed again 3?days after tadalafil discontinuation. The controls were re-evaluated for brachial FMD and EPC counts after 3?months of treatment with placebo. At the end of 3?months of therapy, patients with ED with or without cardiovascular risk factors showed a significant increase in the number of EPCs and an increase in FMD values, whereas the number of circulating EPCs did not change significantly in the controls. Although the study was limited by a lack of randomization, tadalafil treatment seems to improve endothelial function with vasculo-protective effects. The mechanism by which the drug is able to increase EPCs and to restore endothelial function is not known, although at least two hypotheses can be proffered. The first relies on the assumption that PDE5 is present in bone marrow where, once inhibited, may amplify the effects of local NO, which in turn http://www.selleckchem.com/products/ly2157299.html mobilizes stem and progenitor cells. Alternatively, http://www.selleck.cn/products/XL184.html a hypothetical peripheral action of PDE5 inhibitors on the endothelial cells of the vascular tree is modulation of the signalling pathway that leads to EPC activation and/or mobilization. It has also been observed that after treatment with tadalafil, patients with reduced baseline FMD show a less significant increase in EPC counts. This finding suggests that low FMD indicates reduced competence in the mobilization and/or production of EPCs, likely ascribable to alterations of NO-mediated mechanisms that lead to the activation of EPCs. Although the precise mechanism is not certain, one study (Foresta et?al., 2006) suggests that PDE5 inhibitors may play a central role in the prevention and progression of endothelial dysfunction not only in patients with ED but also in patients with cardiovascular disease (CVD). To confirm this hypothesis, a study was conducted on 68 patients with ED and carotid artery damage of various degrees, with 25 men as controls (Foresta et?al., 2007). Patients were divided into three groups according to intima-media thickness (IMT) (i.e. normal, slightly increased, or atherosclerotic plaque). All controls received 20?mg of vardenafil (another PDE5 inhibitor) and underwent EPC count before and 4?sec after the administration of vardenafil. At basal conditions, a significant reduction of circulating EPCs was found in patients with ED compared with the controls.